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MaCell therapy is a promising tool to prevent and treat heart failure in congenital heart disease. We report the first case of
intramyocardial injection of allogeneic mesenchymal stromal cells as rescue therapy in a neonate with ischemic heart
failure following arterial switch procedure for isolated transposition of the great arteries. (Level of Difficulty: Advanced.)
(J Am Coll Cardiol Case Rep 2021;3:724–7) © 2021 The Authors. Published by Elsevier on behalf of the American
College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).HISTORY OF PRESENTATION
A 3.7-kg male neonate underwent an arterial switch
operation for isolated transposition of the great ar-
teries on day 4 of life. Intraoperatively, the left cor-
onary artery (LCA) was found to have a long
intramural course. The patient developed acute left
ventricular (LV) dysfunction after separation from
cardiopulmonary bypass. Refashioning of the LCAEARNING OBJECTIVES
To highlight an uncommon and potentially
fatal complication of the arterial switch
operation.
To illustrate a novel promising application of
cell therapy in patients with CHD.
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artery bypass graft (left internal mammary artery to
left anterior descending coronary artery). Venoarte-
rial extracorporeal membrane oxygenation was
instituted before transferring the patient to the
intensive care unit and successfully discontinued on
post-operative day 6.
MEDICAL HISTORY
The patient had been born at 39 þ 2 weeks of gesta-
tion by normal vaginal delivery and had developed
oxygen desaturation (50% despite fraction of inspired
oxygen of 100%) and hypotension (mean arterial
blood pressure of 25 mm Hg) at 6 h of life. He had then
been diagnosed with transposition of the great ar-
teries with intact ventricular septum. Percutaneoushttps://doi.org/10.1016/j.jaccas.2021.02.039
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AB BR E V I A T I O N S
AND ACRONYM S
CHD = congenital heart disease
FAC = fractional area change
GLS = global longitudinal
strain
LCA = left coronary artery
LV = left ventricular
MSC = mesenchymal stromal
cell
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725balloon atrial septostomy had been undertaken and
surgery had been planned.
DIFFERENTIAL DIAGNOSIS
Acute intraoperative heart failure during the arterial
switch operation is virtually always caused by
myocardial ischemia related to suboptimal coronary
transfer. Severe pulmonary vascular disease is an
uncommon cause of right ventricular failure, which
was not the case in this patient, who had isolated LV
dysfunction.
INVESTIGATIONS
Coronary angiography on post-operative day 2
showed LCA and internal mammary artery occlusion.
Angiography was repeated on post-operative day 50,
confirming the LCA occlusion and demonstrating only
modest collateral circulation from the right coronary
artery (Video 1). Serial transthoracic echocardiograms
were obtained post-operatively to assess the evolu-
tion of LV function (Figure 1).
MANAGEMENT
Over the first 2 post-operative months, the patient
developed inotrope- and ventilator-dependent LV
systolic dysfunction, with failure to thrive and echo-
cardiographic signs of anterolateral LV ischemic
injury, including anterior wall akinesia, a small
anterior wall LV aneurysm, and basal to mid anterior
wall hyperechogenicity.
The patient was deemed suitable for intra-
myocardial injection of allogeneic mesenchymal
stromal cells (MSCs). The treatment was approved on
a compassionate basis by the University Hospital
Bristol and Weston NHS Foundation Trust.
The Centre for Cell, Gene and Tissue Therapeutics
(Royal Free Hospital, University College London) pro-
vided pharmaceutical-grade MSCs. The MSCs were
derived from a single umbilical cord, supplied by the
Anthony Nolan Cord Blood Bank from a registered
volunteer cord blood donor procured under Human
TissueAuthority license.Umbilical cord tissue-derived
MSCs were isolated by plastic adherence, expanded,
and cryopreserved until the day of administration;
they were tested for purity (following International
Society for Cellular Therapy criteria [1]), sterility, and
endotoxin. The drug product was prescribed, manu-
factured, and supplied as an unlicensed medicinal
product (special) in accordance with U.K. law.
MSC injection was undertaken on post-
operative day 60. The anterolateral LV wall was
accessed via a small left anterior thoracotomy. Thetarget dose of 3 million cells/kg body weight
was administered with 4 separate sub-
epicardial injections following a technique
previously used in patients with hypoplastic
left heart syndrome (HLHS) (2). The patient
was extubated and weaned from all intrave-
nous inotropes 16 and 77 days after MSC in-
jection, respectively. He was discharged
home 97 days after the procedure on oral
heart failure therapy and remained clinically
stable.LV ejection fraction was 58% after extracorporeal
membrane oxygenation discontinuation and had
deteriorated to 23% at MSC injection despite inotropic
support. After MSC injection, LV function was moni-
tored mainly with LV fractional area change and LV
global longitudinal strain. Videos 2 and 3 show cor-
responding views of pre-injection and pre-discharge
transthoracic echocardiograms, respectively. Clinical
course and LV function changes after MSC injection
are summarized in Figure 1.
DISCUSSION
Coronary artery abnormalities remain a surgical
challenge when performing the arterial switch oper-
ation, increasing surgical morbidity and mortality
because of myocardial ischemic injury (3).
Cell therapy can be delivered in different ways
according to 3 main parameters. First, a cell type must
be selected. To date, umbilical cord cells, peripheral
blood or bone marrow–derived mononuclear cells,
cardiac stem cells, and MSCs have been used clini-
cally in congenital heart disease (CHD). MSCs can be
easily isolated from different tissues and expanded
in vitro, have intrinsic differentiation potential, and
show marked modulatory properties that are thought
to enhance the host’s regenerative processes, which
is believed to be more important than the MSC
expansion itself. It is known that MSCs can stimulate
recovery from cardiac injury through paracrine ac-
tivity, promoting reduction of fibrosis, neo-
vascularization, immunomodulation, and stimulation
of endogenous tissue regeneration (4).
Second, the selected cells can be of autologous or
allogeneic origin. The main theoretical advantage of
autologous cells is their immunologic compatibility;
nevertheless, there is little evidence that allogeneic
MSCs, which express low levels of major histocom-
patibility complex class I and lack major histocom-
patibility complex class II antigens, induce
alloantibodies. In contrast, the immediate availability
of allogeneic cells renders them more feasible in an
FIGURE 1 Clinical Events and LV Function
(A) Hospital course and (B) evolution of left ventricular (LV) function after intramyocardial mesenchymal stromal cell (MSC) injection to
palliate ischemic heart failure following arterial switch operation. The blue line on the plot represents LV global longitudinal strain, and the
red line represents LV fractional area change measured by transthoracic echocardiography. ECMO ¼ extracorporeal membrane oxygenation.
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726urgent setting. Moreover, the recent POSEIDON-DCM
(Percutaneous Stem Cell Injection Delivery Effects on
Neomyogenesis in Dilated Cardiomyopathy) ran-
domized trial showed superiority of allogeneic MSCs
over autologous MSCs in an adult cohort of patients
with dilated cardiomyopathy, possibly due to better
modulatory properties (5).
Third, the route of delivery must be chosen; to
date, intramyocardial and intracoronary administra-
tion have been undertaken clinically (6).
Cell therapy has been used in preclinical models of
CHD and showed initial promising results in patients
with hypoplastic left heart syndrome (2,7–9). To the
best of our knowledge, this is the first report of suc-
cessful use of allogeneic MSCs for inotrope- and
ventilator-dependent ischemic heart failure following
arterial switch operation. Our choice to use allogeneic
cells was driven mainly by the urgent scenario;
intramyocardial delivery was dictated by the occlu-
sion of the LCA.
MSC injection does not resolve the culprit coro-
nary lesion, and the exact mechanism of action in
this particular patient cannot be precisely demon-
strated. However, we observed a correlation between
MSC injection and the patient’s clinical improve-
ment; the rationale behind this specific application is
that boosts of MSCs may aid the ischemic myocar-
dium, thanks to their acknowledged proangiogenic
activity.FOLLOW-UP
One year after arterial switch, the patient remains on
oral heart failure therapy with no clinical signs of
ongoing myocardial ischemia, and he has been
growing along the ninth weight centile. LV function is
mildly impaired (Figure 1).
CONCLUSIONS
Cell therapy is an emerging therapeutic strategy in
patients with CHD. Its medium- and long-term results
are not known, and further studies are needed to
delineate potential candidates and outcomes in the
pediatric population.
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